Cargando…
All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease
AIMS: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden. METHODS: We tested whether ENFORCE, an established prediction model o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164049/ https://www.ncbi.nlm.nih.gov/pubmed/34050821 http://dx.doi.org/10.1007/s00592-021-01746-2 |
_version_ | 1783701032008679424 |
---|---|
author | Copetti, Massimiliano Biancalana, Edoardo Fontana, Andrea Parolini, Federico Garofolo, Monia Lamacchia, Olga De Cosmo, Salvatore Trischitta, Vincenzo Solini, Anna |
author_facet | Copetti, Massimiliano Biancalana, Edoardo Fontana, Andrea Parolini, Federico Garofolo, Monia Lamacchia, Olga De Cosmo, Salvatore Trischitta, Vincenzo Solini, Anna |
author_sort | Copetti, Massimiliano |
collection | PubMed |
description | AIMS: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden. METHODS: We tested whether ENFORCE, an established prediction model of all-cause mortality in type 2 diabetes, performs well also in two independent samples of patients with early-stage disease prospectively followed up. RESULTS: ENFORCE’s survival C-statistic was 0.81 (95%CI: 0.72–0.89) and 0.78 (95%CI: 0.68–0.87) in both samples. Calibration was also good. Very similar results were obtained with RECODe, an alternative prediction model of all-cause mortality in type 2 diabetes. CONCLUSIONS: In conclusion, our data show that two well-established prediction models of all-cause mortality in type 2 diabetes can also be successfully applied in the early stage of the disease, thus becoming powerful tools for educated and timely prevention strategies for high-risk patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-021-01746-2. |
format | Online Article Text |
id | pubmed-8164049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-81640492021-06-01 All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease Copetti, Massimiliano Biancalana, Edoardo Fontana, Andrea Parolini, Federico Garofolo, Monia Lamacchia, Olga De Cosmo, Salvatore Trischitta, Vincenzo Solini, Anna Acta Diabetol Original Article AIMS: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden. METHODS: We tested whether ENFORCE, an established prediction model of all-cause mortality in type 2 diabetes, performs well also in two independent samples of patients with early-stage disease prospectively followed up. RESULTS: ENFORCE’s survival C-statistic was 0.81 (95%CI: 0.72–0.89) and 0.78 (95%CI: 0.68–0.87) in both samples. Calibration was also good. Very similar results were obtained with RECODe, an alternative prediction model of all-cause mortality in type 2 diabetes. CONCLUSIONS: In conclusion, our data show that two well-established prediction models of all-cause mortality in type 2 diabetes can also be successfully applied in the early stage of the disease, thus becoming powerful tools for educated and timely prevention strategies for high-risk patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-021-01746-2. Springer Milan 2021-05-29 2021 /pmc/articles/PMC8164049/ /pubmed/34050821 http://dx.doi.org/10.1007/s00592-021-01746-2 Text en © Springer-Verlag Italia S.r.l., part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Copetti, Massimiliano Biancalana, Edoardo Fontana, Andrea Parolini, Federico Garofolo, Monia Lamacchia, Olga De Cosmo, Salvatore Trischitta, Vincenzo Solini, Anna All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease |
title | All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease |
title_full | All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease |
title_fullStr | All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease |
title_full_unstemmed | All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease |
title_short | All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease |
title_sort | all-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164049/ https://www.ncbi.nlm.nih.gov/pubmed/34050821 http://dx.doi.org/10.1007/s00592-021-01746-2 |
work_keys_str_mv | AT copettimassimiliano allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease AT biancalanaedoardo allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease AT fontanaandrea allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease AT parolinifederico allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease AT garofolomonia allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease AT lamacchiaolga allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease AT decosmosalvatore allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease AT trischittavincenzo allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease AT solinianna allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease |